Global Access and Partnership Program
At Janssen, we are committed to helping people living with HIV in resource-limited settings by ensuring effective and sustainable access to our HIV medicines, or antiretrovirals (ARVs). We believe that effective HIV drug access has two important components: ensuring quality and affordable medicines are available sustainably and that they are used safely and in the most appropriate way for people living with HIV/AIDS (PLWHA).
Through our comprehensive HIV drug access framework, our Global Access and Partnerships Program works to fulfill this responsibility to PLWHA in resource-limited countries, such as in sub-Saharan Africa (SSA), least developed countries (LDCs), and lower middle-income countries (LMICs). This includes:
- Operating on a sustainable, not-for-profit basis
- Licensing for both branded and generic versions of our HIV medicines
- Prioritizing regulatory filings where there is public health need
- Supporting the optimal, appropriate and safe use of our HIV medicines
We invite you to learn more about the Global Access and Partnership Program and supporting access activities by viewing our 2012 brochure and information on our licensing agreements and collaborations.